文献速递免疫规划传染病防控与疫情报告

基于乙肝核心抗原的三价VLP疫苗抗猪病毒性腹泻

Hepatitis B core antigen-based trivalent VLP vaccine against porcine viral diarrhea.
PubMed 文献 · Vaccine · 2026-01-10

本研究将TGEV、PEDV和PoRV的保守线性中和表位分别整合到截短型乙肝核心抗原单体上,构建三价病毒样颗粒(triVLP)疫苗,并在BALB/c小鼠中评估25 μg和50 μg两个剂量的免疫原性。结果显示50 μg triVLP组在免疫后35天血清IFN-γ和IL-4水平显著高于25 μg组,且针对三种病毒的IgG和病毒中和抗体滴度显著高于商业三价减毒疫苗组。

要点

  • 50 μg triVLP诱导的细胞免疫(IFN-γ、IL-4)显著强于25 μg组。
  • 50 μg triVLP组针对TGEV、PEDV、PoRV的IgG和中和抗体滴度显著高于商业三价减毒疫苗。
  • HBcAg三价VLP是猪病毒性腹泻的候选疫苗。

核心结论

  • 基于HBcAg的三价VLP能诱导强烈的细胞和体液免疫,是猪病毒性腹泻的候选疫苗。

研究设计与样本

  • 将TGEV、PEDV和PoRV的保守线性中和表位分别整合到截短型HBcAg单体上构建triVLP,在BALB/c小鼠中评估25 μg和50 μg两个剂量的免疫原性。

主要发现

  • 免疫后35天,50 μg triVLP组血清IFN-γ和IL-4水平显著高于25 μg组。
  • 免疫后35天,50 μg triVLP组针对TGEV、PEDV和PoRV的IgG和病毒中和抗体滴度显著高于商业三价减毒疫苗组。

关键数值与推荐

  • triVLP剂量为25 μg和50 μg,免疫后35天评估细胞免疫和体液免疫指标。

临床怎么用

  • 提示HBcAg三价VLP可作为猪病毒性腹泻的候选疫苗,高剂量(50 μg)免疫效果更优。

局限性

  • 研究仅在小鼠中评估免疫原性,未报告攻击保护试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine viral diarrhea imposes substantial economic burdens on the swine industry. The commercial triplex-attenuated vaccine against TGEV, PEDV, and PoRV infections has limitations in preparation and efficacy. The Hepatitis B virus core antigen (HBcAg), known for its ability to self-assemble into virus-like particles (VLPs) in vitro and stably present exogenous antigens, serves as a critical technical foundation for the development of innovative nano-vaccines. In this study, we strategically concatenated truncated and full-length monomers of HBcAg, with the conserved linear neutralizing epitopes from TGEV, PEDV, and PoRV being respectively integrated exclusively into the truncated variants to develop a trivalent-VLP (triVLP) vaccine candidate for porcine viral diarrhea. The immunogenicity of triVLPs at two distinct dosages (25 μg and 50 μg) was then evaluated in BALB/c mice following their administration. Notably, the higher dosage of 50 μg triVLP was found to significantly enhance cellular immunity compared to the 25 μg triVLP group, as evidenced by the substantial increase in serum levels of IFN-γ and IL-4 observed at 35 days post-immunization (dpi). Furthermore, at 35 dpi, the IgG and virus neutralizing (VN) antibody titers against TGEV, PEDV, and PoRV in the 50 μg triVLP group were significantly higher than those observed in the group receiving the commercial triplex-attenuated vaccine, indicating a pronounced humoral immune response. Collectively, our data indicate that HBcAg-based trivalent VLPs elicit potent cellular and humoral immunity, positioning them as a prospective vaccine candidate for porcine viral diarrhea.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sheng S, Sun Y, Qin J, et al. Hepatitis B core antigen-based trivalent VLP vaccine against porcine viral diarrhea. Vaccine. 2026. PMID: 41520424. doi:10.1016/j.vaccine.2026.128210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。